Title | SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Corporate Authors | SCORE2-OP working group and ESC Cardiovascular risk collaboration |
Journal | Eur Heart J |
Volume | 42 |
Issue | 25 |
Pagination | 2455-2467 |
Date Published | 2021 07 01 |
ISSN | 1522-9645 |
Keywords | Aged, Aged, 80 and over, Algorithms, Blood Pressure, Cardiovascular Diseases, Female, Humans, Male, Myocardial Infarction, Risk Assessment, Risk Factors, Stroke |
Abstract | AIMS: The aim of this study was to derive and validate the SCORE2-Older Persons (SCORE2-OP) risk model to estimate 5- and 10-year risk of cardiovascular disease (CVD) in individuals aged over 70 years in four geographical risk regions. METHODS AND RESULTS: Sex-specific competing risk-adjusted models for estimating CVD risk (CVD mortality, myocardial infarction, or stroke) were derived in individuals aged over 65 without pre-existing atherosclerotic CVD from the Cohort of Norway (28 503 individuals, 10 089 CVD events). Models included age, smoking status, diabetes, systolic blood pressure, and total- and high-density lipoprotein cholesterol. Four geographical risk regions were defined based on country-specific CVD mortality rates. Models were recalibrated to each region using region-specific estimated CVD incidence rates and risk factor distributions. For external validation, we analysed data from 6 additional study populations {338 615 individuals, 33 219 CVD validation cohorts, C-indices ranged between 0.63 [95% confidence interval (CI) 0.61-0.65] and 0.67 (0.64-0.69)}. Regional calibration of expected-vs.-observed risks was satisfactory. For given risk factor profiles, there was substantial variation across the four risk regions in the estimated 10-year CVD event risk. CONCLUSIONS: The competing risk-adjusted SCORE2-OP model was derived, recalibrated, and externally validated to estimate 5- and 10-year CVD risk in older adults (aged 70 years or older) in four geographical risk regions. These models can be used for communicating the risk of CVD and potential benefit from risk factor treatment and may facilitate shared decision-making between clinicians and patients in CVD risk management in older persons. |
DOI | 10.1093/eurheartj/ehab312 |
Alternate Journal | Eur Heart J |
PubMed ID | 34120185 |
PubMed Central ID | PMC8248997 |
Grant List | 75N95020D00003 / DA / NIDA NIH HHS / United States HHSN268201500003C / HL / NHLBI NIH HHS / United States N01HC95160 / HL / NHLBI NIH HHS / United States N01HC95163 / HL / NHLBI NIH HHS / United States 75N93020D00002 / AI / NIAID NIH HHS / United States N01HC95169 / HL / NHLBI NIH HHS / United States N01HC95162 / HL / NHLBI NIH HHS / United States N01HC95166 / HL / NHLBI NIH HHS / United States 75N95020D00004 / DA / NIDA NIH HHS / United States 75N99020D00004 / OF / ORFDO NIH HHS / United States HHSN268200900048C / HL / NHLBI NIH HHS / United States 75N90020D00002 / CL / CLC NIH HHS / United States HHSN268200900040C / HL / NHLBI NIH HHS / United States HHSN268200900046C / HL / NHLBI NIH HHS / United States UL1 TR001079 / TR / NCATS NIH HHS / United States 75N96020D00002 / ES / NIEHS NIH HHS / United States 75N99020D00003 / OF / ORFDO NIH HHS / United States 75N95020D00002 / DA / NIDA NIH HHS / United States N01HC95164 / HL / NHLBI NIH HHS / United States / AG / NIA NIH HHS / United States N01HC95168 / HL / NHLBI NIH HHS / United States 75N90020D00003 / CL / CLC NIH HHS / United States 75N96020D00003 / ES / NIEHS NIH HHS / United States HHSN268200900049C / HL / NHLBI NIH HHS / United States HHSN268201700001I / NH / NIH HHS / United States HHSN268200900047C / HL / NHLBI NIH HHS / United States 75N99020D00002 / OF / ORFDO NIH HHS / United States HHSN268201700002C / HL / NHLBI NIH HHS / United States HHSN268201700001I / HL / NHLBI NIH HHS / United States 75N99020D00006 / OF / ORFDO NIH HHS / United States HHSN268201700004I / HL / NHLBI NIH HHS / United States / BHF_ / British Heart Foundation / United Kingdom N01HC95165 / HL / NHLBI NIH HHS / United States N01HC95159 / HL / NHLBI NIH HHS / United States 75N95020D00007 / DA / NIDA NIH HHS / United States / NS / NINDS NIH HHS / United States N01HC95161 / HL / NHLBI NIH HHS / United States UL1 TR001420 / TR / NCATS NIH HHS / United States 75N95020D00005 / DA / NIDA NIH HHS / United States UL1-TR-000040 / NH / NIH HHS / United States HHSN268201500003I / HL / NHLBI NIH HHS / United States 75N92021D00006 / HL / NHLBI NIH HHS / United States HHSN268201700005C / HL / NHLBI NIH HHS / United States HHSN268201700001C / HL / NHLBI NIH HHS / United States 75N99020D00005 / OF / ORFDO NIH HHS / United States N01HC95167 / HL / NHLBI NIH HHS / United States HHSN268201700003C / HL / NHLBI NIH HHS / United States 75N92020D00001 / NH / NIH HHS / United States 75N99020D00007 / OF / ORFDO NIH HHS / United States HHSN268201700004C / HL / NHLBI NIH HHS / United States UL1 TR000040 / TR / NCATS NIH HHS / United States HHSN268201700002I / HL / NHLBI NIH HHS / United States HHSN268201700005I / HL / NHLBI NIH HHS / United States 75N98020D00007 / OD / NIH HHS / United States HHSN268201700003I / HL / NHLBI NIH HHS / United States / DK / NIDDK NIH HHS / United States RG/18/13/33946 / BHF_ / British Heart Foundation / United Kingdom |